# Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

> **NCT02036970** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 166 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Interstitial Lung Disease
- Idiopathic Interstitial Pneumonia
- Idiopathic Pulmonary Fibrosis
- Sarcoidosis
- Respiratory Bronchiolitis Associated Interstitial Lung Disease
- Desquamative Interstitial Pneumonia
- Cryptogenic Organizing Pneumonia
- Acute Interstitial Pneumonitis
- Idiopathic Lymphoid Interstitial Pneumonia
- Idiopathic Pleuroparenchymal Fibroelastosis

## Interventions

- **DRUG:** Bardoxolone methyl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02036970
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-31
- **Primary completion:** 2018-01-19
- **Final completion:** 2018-05-16
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02036970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02036970, "Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT02036970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*